Cancer drug trial halted: TNG908 shows promise but study ends early
Disease control
Terminated
This study tested an experimental oral drug called TNG908 in people with advanced solid tumors that have a missing MTAP gene. The goal was to find a safe dose and see if the drug could shrink tumors. The trial was terminated early, so results are limited, but it aimed to help pat…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC